Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06168487 · ClinicalTrials.gov registry record · Phase 1
Telmisartan in Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Tyler J Curiel.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06168487 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by Tyler J Curiel. The registered enrollment target is 36 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06168487, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by Tyler J Curiel.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
Conditions Studied
Interventions
- DRUG Telmisartan
- OTHER Standard of Care Regimen
Study Locations (1)
New Hampshire
- Dartmouth Health - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06168487
The ClinicalTrials.gov registry entry for NCT06168487 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Tyler J Curiel, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Telmisartan is the first listed.
NCT06168487 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06168487 about?
NCT06168487 is a clinical study titled "Telmisartan in Prostate Cancer". The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
What is the current status of trial NCT06168487?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-04-22. Estimated completion is 2027-04-01.
What conditions does trial NCT06168487 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06168487?
The interventions under investigation include: Telmisartan (DRUG), Standard of Care Regimen (OTHER).
Who is sponsoring clinical trial NCT06168487?
This trial is sponsored by Tyler J Curiel, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06168487 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.